NCT06413511View on ClinicalTrials.gov

A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 3, 2024

Primary Completion Date

July 8, 2025

Study Completion Date

July 8, 2025

Conditions
Autoimmune Diseases
Interventions
BIOLOGICAL

Belantamab

Belantamab will be administered

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT06413511 - A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease | Biotech Hunter | Biotech Hunter